NDLI: Clinical-genomic characteristics of homologous recombination deficiency (HRD) in breast cancer: application model for practice

Content Provider	Springer Nature : BioMed Central
Author	Du, Jinsui Zhu, Lizhe Duan, Chenglong Ma, Nan Zhou, Yudong Li, Danni Zhang, Jianing Zhang, Jiaqi Wang, Yalong Liu, Xi Ren, Yu Wang, Bin
Abstract	Background Homologous recombination deficiency (HRD) affects breast cancer patients. Treatment guided by multigene testing may be particularly beneficial in HRD patients by using platinum-based drugs and poly ADP-ribose polymerase inhibitor (PARPi). However, the optimal method for HRD testing remains undetermined by guidelines or consensus and economic disparities limit the availability of genetic testing. Prioritizing HRD testing by clinical-genomic characteristics is critical for efficient utilization of healthcare resources and improved treatment accuracy. Methods A total of 93 breast cancer patients who underwent HRD genetic testing were included in the study. According to the machine learning model called genomic scar (GS) HRD was defined as a genomic scar score (GSS) ≥ 50 or with deleterious mutation in the BRCA. Multivariate logistic regression analysis was employed to identify the clinical-pathological factors potentially associated with HRD. Suitable variables were selected to construct a predictive model, and the model’s efficacy was evaluated using the area under the receiver operating characteristic (ROC) curve. Internal validation was performed using bootstrap resampling (500 replicates). Results Patients harboring pathogenic mutation in BRCA exhibited higher GSS (99.85 vs 36.90). HRD was not detected in 41.75% of patients, and 34.95% had HRD but no BRCA pathogenic mutations. HRD risk in human epidermal factor growth receptor 2 (HER2) low or positive was significantly lower compared to HER2 negative (OR: 0.390, 95% CI: 0.159–0.959, P = 0.040). High Ki- 67 index was strongly associated with HRD (OR: 28.434, 95% CI: 3.283–246.293, P = 0.002). Significant variations in GSS were observed based on estrogen receptor (ER) and progesterone receptor (PR) status, histological grade, and molecular types. The area under the ROC curve (AUC) of the combined prediction model combining HER2 status and Ki- 67 index was 0.749, and the accuracy of the model was further validated using bootstrap resampling (500 replicates), resulting in an AUC of 0.730, indicating a high predictive accuracy for HRD status. Conclusions BRCA mutation status did not fully reflect HRD status. Patients with a negative HER2 status and high Ki- 67 index are more likely to exhibit positive results when undergoing HRD genetic testing. The ER, PR, HER- 2 status, Ki- 67 index, molecular typing, and histological grading may have a strong influence on the HRD status.
Related Links	https://eurjmedres.biomedcentral.com/counter/pdf/10.1186/s40001-025-02520-8.pdf
Ending Page	11
Page Count	11
Starting Page	1
File Format	HTM / HTML
DOI	10.1186/s40001-025-02520-8
Journal	European Journal of Medical Research
Issue Number	1
Volume Number	30
Language	English
Publisher	BioMed Central
Publisher Date	2025-04-07
Access Restriction	Open
Subject Keyword	Medicine Public Health Infectious Diseases Internal Medicine Surgery Oncology Biomedicine BRCA Homologous recombination deficiency Breast cancer Genomic scar score Clinical-genomic characteristics Medicine/Public Health
Content Type	Text
Resource Type	Article
Subject	Medicine
Journal Impact Factor	2.8/2023
5-Year Journal Impact Factor	2.9/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score.

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.

Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)

Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics

The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair

Biomarkers for Homologous Recombination Deficiency in Cancer

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers

Homologous recombination proficiency in ovarian and breast cancer patients

In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.

Clinical-genomic characteristics of homologous recombination deficiency (HRD) in breast cancer: application model for practice

Similar Documents

Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score.

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.

Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)

Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics

The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair

Biomarkers for Homologous Recombination Deficiency in Cancer

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers

Homologous recombination proficiency in ovarian and breast cancer patients

In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.

Clinical-genomic characteristics of homologous recombination deficiency (HRD) in breast cancer: application model for practice